Generic Famotidine Launch Delayed By Pepcid AC Pediatric Exclusivity
This article was originally published in The Tan Sheet
Executive Summary
Private label famotidine 10 mg products will not launch until after April 15 due to FDA's Nov. 21 decision to grant J&J/Merck an additional six months of marketing exclusivity for Pepcid AC after reviewing pediatric data submitted by the firm.
You may also be interested in...
Pediatric Exclusivity Could Be Out-Licensed To Other Sponsors, FDA Suggests
Congress should consider allowing pediatric exclusivity periods to be licensed to other sponsors as a mechanism for promoting pediatric study of drug products that do not have patent protection or exclusivity, FDA's pediatric exclusivity status report suggests.
Private label famotidine
Cheminor Drugs receives tentative approval from FDA Dec. 13 for OTC famotidine 10 mg tablets (ANDA 75-758). Reference drug is J&J/Merck's Pepcid AC, which recently was granted additional six months of exclusivity based on pediatric data submitted by firm, postponing market entry of generic versions of H2 antagonist until April 15. Both Teva Pharmaceuticals and Danbury Pharmacal also have tentative approvals; Perrigo, PFI, Leiner and Zenith Goldline intend to offer generic famotidine in 2001 (1"The Tan Sheet" Nov. 27, p. 11)
W-L Allergy/Cold Brands Help Offset Struggling Zantac 75 Sales In 1Q
The recently extended Benadryl franchise led the way in a strong first quarter for Warner-Lambert's stable of allergy/cold products.